Economic burden of systemic lupus erythematosus in Malaysia

References

• Shaikh MF, Jordan N, D'Cruz DP. Systemic lupus erythematosus. Clin Med. 2017;17(1):78–83. doi: 10.7861/clinmedicine.17-1-78.
   PubMed Web of Science ®Google Scholar
• Schmeding A, Schneider M. Fatigue, health-related quality of life and other patient-reported outcomes in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2013;27(3):363–375. doi: 10.1016/j.berh.2013.07.009.
   PubMed Web of Science ®Google Scholar
• Garris C, Jhingran P, Bass D, et al. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan. J Med Econ. 2013;16(5):667–677. doi: 10.3111/13696998.2013.778270.
   PubMedGoogle Scholar
• Li T, Carls GS, Panopalis P, et al. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population. Arthritis Rheum. 2009;61(6):755–763. doi: 10.1002/art.24545.
   PubMedGoogle Scholar
• Kan HJ, Song X, Johnson BH, et al. Healthcare utilization and costs of systemic lupus erythematosus in medicaid. Biomed Res Int. 2013;2013:808391–808398. doi: 10.1155/2013/808391.
   PubMed Web of Science ®Google Scholar
• Osio-Salido E, Manapat-Reyes H. Epidemiology of systemic lupus erythematosus in asia. Lupus. 2010;19(12):1365–1373. doi: 10.1177/0961203310374305.
   PubMed Web of Science ®Google Scholar
• Tian J, Zhang D, Yao X, et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023;82(3):351–356. doi: 10.1136/ard-2022-223035.
   PubMed Web of Science ®Google Scholar
• Teh C, Ling G. Causes and predictors of mortality in hospitalized lupus patient in Sarawak general hospital, Malaysia. Lupus. 2013;22(1):106–111. doi: 10.1177/0961203312465780.
   PubMed Web of Science ®Google Scholar
• D'Cruz DP. Systemic lupus erythematosus. BMJ. 2006;332(7546):890–894. doi: 10.1136/bmj.332.7546.890.
   PubMedGoogle Scholar
• Björk M, Dahlström Ö, Wetterö J, et al. Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus. BMC Musculoskelet Disord. 2015;16(1):188. doi: 10.1186/s12891-015-0621-3.
   PubMedGoogle Scholar
• Murimi-Worstell IB, Lin DH, Nab H, et al. Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis. BMJ Open. 2020;10(5):e031850. doi: 10.1136/bmjopen-2019-031850.
   PubMed Web of Science ®Google Scholar
• Chiu YM, Chuang MT, Lang HC. Medical costs incurred by organ damage caused by active disease, comorbidities and side effect of treatments in systemic lupus erythematosus patients: a Taiwan nationwide population-based study. Rheumatol Int. 2016;36(11):1507–1514. doi: 10.1007/s00296-016-3551-y.
   PubMed Web of Science ®Google Scholar
• Urowitz MB, Gladman DD, Ibañez D, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res. 2012;64(1):132–137. doi: 10.1002/acr.20648.
   PubMed Web of Science ®Google Scholar
• Bultink IE, Turkstra F, Dijkmans BA, et al. High prevalence of unemployment in patients with systemic lupus erythematosus: association with organ damage and health-related quality of life. J Rheumatol. 2008;35(6):1053–1057.
   PubMed Web of Science ®Google Scholar
• Kuhn A, Bonsmann G, Anders HJ, et al. The diagnosis and treatment of systemic lupus erythematosus. Dtsch Arztebl Int. 2015;112(25):423–432. doi: 10.3238/arztebl.2015.0423.
   PubMed Web of Science ®Google Scholar
• Adamichou C, Bertsias G. Flares in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies. Mediterr J Rheumatol. 2017;28(1):4–12. doi: 10.31138/mjr.28.1.4.
   PubMedGoogle Scholar
• Katz P, Nelson WW, Daly RP, et al. Patient-Reported lupus flare symptoms are associated with worsened patient outcomes and increased economic burden. J Manag Care Spec Pharm. 2020;26(3):275–283. doi: 10.18553/jmcp.2020.26.3.275.
   PubMed Web of Science ®Google Scholar
• Bertsias G, Karampli E, Sidiropoulos P, et al. Clinical and financial burden of active lupus in Greece: a nationwide study. Lupus. 2016;25(12):1385–1394. doi: 10.1177/0961203316642310.
   PubMed Web of Science ®Google Scholar
• Jiang M, Near AM, Desta B, et al. et alDisease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004. Lupus Sci Med. 2021;8(1):e000503. doi: 10.1136/lupus-2021-000503.
   PubMed Web of Science ®Google Scholar
• Albrecht K, Redeker I, Aringer M, et al. Comorbidity and healthcare utilisation in persons with incident systemic lupus erythematosus followed for 3 years after diagnosis: analysis of a claims data cohort. Lupus Sci Med. 2021;8(1):e000526. doi: 10.1136/lupus-2021-000526.
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British isles lupus assessment group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology. 2005;44(7):902–906. doi: 10.1093/rheumatology/keh624.
   PubMed Web of Science ®Google Scholar
• World Bank. Population ages 15–64, total – Malaysia. 2023. https://data.worldbank.org/indicator/SP.POP.1564.TO?locations=MY
   Google Scholar
• World Bank. Population ages 65 and above, total – Malaysia. 2023. https://data.worldbank.org/indicator/SP.POP.65UP.TO?locations=MY.
   Google Scholar
• Nikolopoulos DS, Kostopoulou M, Pieta A, et al. Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease. Lupus Sci Med. 2020;7(1):e000394. doi: 10.1136/lupus-2020-000394.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)–explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–250. doi: 10.1016/j.jval.2013.02.002.
   PubMed Web of Science ®Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices–overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Med Decis Making. 2012;32(5):667–677. doi: 10.1177/0272989X12454577.
   PubMed Web of Science ®Google Scholar
• Sim R, Chong CW, Loganadan NK, et al. Cost-effectiveness of glucose-lowering therapies as add-on to standard care for people with type 2 diabetes in Malaysia. Value Health Reg Issues. 2023;38:9–17. doi: 10.1016/j.vhri.2023.05.006.
   PubMedGoogle Scholar
• Castro-Villarreal S, Beltran-Ostos A, Valencia CF. Estimation of prevalence and incremental costs of systemic lupus erythematosus in a middle-income country using machine learning on administrative health data. Value Health Reg Issues. 2021;26:98–104. doi: 10.1016/j.vhri.2021.04.005.
   PubMedGoogle Scholar
• Giannouli S, Voulgarelis M, Ziakas PD, et al. Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. Ann Rheum Dis. 2006;65(2):144–148. doi: 10.1136/ard.2005.041673.
   PubMed Web of Science ®Google Scholar
• Jasmin R, Sockalingam S, Cheah TE, et al. Systemic lupus erythematosus in the multiethnic Malaysian population: disease expression and ethnic differences revisited. Lupus. 2013;22(9):967–971. doi: 10.1177/0961203313496299.
   PubMed Web of Science ®Google Scholar
• Shaharir SS, Hussein H, Rajalingham S, et al. Damage in the multiethnic Malaysian systemic lupus erythematosus (SLE) cohort: comparison with other cohorts worldwide. PLOS One. 2016;11(11):e0166270. doi: 10.1371/journal.pone.0166270.
   PubMed Web of Science ®Google Scholar
• Urowitz MB, Gladman D, Ibañez D, et al. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus. 2007;16(9):731–735. doi: 10.1177/0961203307081113.
   PubMed Web of Science ®Google Scholar
• Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol. 2016;68(6):1432–1441. doi: 10.1002/art.39594.
   PubMed Web of Science ®Google Scholar
• Hammond ER, Desta B, Near AM, et al. Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004-2015. Lupus Sci Med. 2021;8(1):e000504. doi: 10.1136/lupus-2021-000504.
   PubMed Web of Science ®Google Scholar
• Ko T, Koelmeyer R, Li N, et al. Predictors of infection requiring hospitalization in patients with systemic lupus erythematosus: a time-to-event analysis. Semin Arthritis Rheum. 2022;57:152099. doi: 10.1016/j.semarthrit.2022.152099.
   PubMed Web of Science ®Google Scholar
• Heo JY, Seo YB, Choi WS, et al. Effectiveness of pneumococcal vaccination against pneumococcal pneumonia hospitalization in older adults: a prospective, test-negative study. J Infect Dis. 2022;225(5):836–845. doi: 10.1093/infdis/jiab474.
   PubMed Web of Science ®Google Scholar
• The World Bank. Gender data portal. 2023. https://genderdata.worldbank.org/countries/malaysia/
   Google Scholar
• Drenkard C, Bao G, Dennis G, et al. Burden of systemic lupus erythematosus on employment and work productivity: data from a large cohort in the southeastern United States. Arthritis Care Res. 2014;66(6):878–887. doi: 10.1002/acr.22245.
   Web of Science ®Google Scholar
• Utset TO, Baskaran A, Segal BM, et al. Work disability, lost productivity and associated risk factors in patients diagnosed with systemic lupus erythematosus. Lupus Sci Med. 2015;2(1):e000058–e000058. doi: 10.1136/lupus-2014-000058.
   PubMedGoogle Scholar
• The World Bank. GDP per capita (Constant LCU)-Malaysia. 2023. https://data.worldbank.org/indicator/NY.GDP.PCAP.KN?locations=MY
   Google Scholar
• Amissah-Arthur MB, Gordon C. Contemporary treatment of systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis. 2010;1(4):163–175. doi: 10.1177/2040622310380100.
   PubMedGoogle Scholar
• Karim MY, Alba P, Cuadrado M‐J, et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology. 2002;41(8):876–882. doi: 10.1093/rheumatology/41.8.876.
   PubMed Web of Science ®Google Scholar
• Porta S, Danza A, Arias Saavedra M, et al. Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues. J Clin Med. 2020;9(9):2709. doi: 10.3390/jcm9092709.
   PubMed Web of Science ®Google Scholar
• Kernder A, Richter JG, Fischer-Betz R, et al. Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: cross sectional analysis of the LuLa cohort. Lupus. 2021;30(3):431–438. doi: 10.1177/0961203320983445.
   PubMed Web of Science ®Google Scholar
• Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet. 1999;354(9196):2106–2111. doi: 10.1016/S0140-6736(99)02332-6.
   PubMed Web of Science ®Google Scholar
• Abu Bakar F, Sazliyana Shaharir S, Mohd R, et al. Burden of systemic lupus erythematosus on work productivity and daily living activity: a cross-sectional study among Malaysian multi-ethnic cohort. Arch Rheumatol. 2020;35(2):205–213. doi: 10.46497/ArchRheumatol.2020.7405.
   PubMed Web of Science ®Google Scholar
• Jönsen A, Hjalte F, Willim M, et al. Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts. Semin Arthritis Rheum. 2016;45(6):684–690. doi: 10.1016/j.semarthrit.2015.11.013.
   PubMed Web of Science ®Google Scholar
• Jönsen A, Bengtsson AA, Hjalte F, et al. Total cost and cost predictors in systemic lupus erythematosus - 8-years follow-up of a Swedish inception cohort. Lupus. 2015;24(12):1248–1256. doi: 10.1177/0961203315584812.
   PubMed Web of Science ®Google Scholar
• Koelmeyer R, Nim HT, Nikpour M, et al. High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus lupus. Lupus Sci Med. 2020;7(1):e000372. doi: 10.1136/lupus-2019-000372.
   PubMed Web of Science ®Google Scholar
• Murimi-Worstell IB, Lin DH, Kan H, et al. Healthcare utilization and costs of systemic lupus erythematosus by disease severity in the United States. J Rheumatol. 2021;48(3):385–393. doi: 10.3899/jrheum.191187.
   PubMed Web of Science ®Google Scholar
• Hanly JG, O'Keeffe AG, Su L, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology. 2016;55(2):252–262. doi: 10.1093/rheumatology/kev311.
   PubMed Web of Science ®Google Scholar
• Bell CF, Huang SP, Cyhaniuk A, et al. The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States. Lupus. 2023;32(2):301–309. doi: 10.1177/09612033221146093.
   PubMed Web of Science ®Google Scholar
• Bell CF, Wu B, Huang SP, et al. Healthcare resource utilization and associated costs in patients with systemic lupus erythematosus diagnosed with lupus nephritis. Cureus. 2023;15(4):e37839. doi: 10.7759/cureus.37839.
   PubMed Web of Science ®Google Scholar
• Özsungur F. The psychological effects of systemic lupus erythematosus: the imitator of aging. LymphoSign J. 2020;7(1):37–45. doi: 10.14785/lymphosign-2019-0016.
   Google Scholar
• Al Sawah S, Daly RP, Foster SA, et al. The caregiver burden in lupus: findings from UNVEIL, a national online lupus survey in the United States. Lupus. 2017;26(1):54–61. doi: 10.1177/0961203316651743.
   PubMed Web of Science ®Google Scholar
• Chambers SA, Allen E, Rahman A, et al. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology. 2009;48(6):673–675. doi: 10.1093/rheumatology/kep062.
   PubMed Web of Science ®Google Scholar
• Barber MRW, Hanly JG, Su L, et al. Economic evaluation of damage accrual in an international systemic lupus erythematosus inception cohort using a multistate model approach. Arthritis Care Res. 2020;72(12):1800–1808. doi: 10.1002/acr.24092.
   Web of Science ®Google Scholar
• International Trade Administration. Malaysia Healthcare Government Plan. 2024. https://www.trade.gov/market-intelligence/malaysia-healthcare-government-plan.
   Google Scholar